We next tested the interaction of CK1α inhibition with Duvelisib, a PI3Kγ/δ inhibitor approved for the treatment of Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphoma (FL). This evidence concerns the gene CSNK1A1 and follicular lymphoma.